Startups

An $11.5M Series C will help Gliknik advance 3 treatments for cancer, autoimmune disease

The University of Maryland BioPark-based company has now raised $81M million total.

The University of Maryland BioPark. (Courtesy photo)

Add a company based in Baltimore’s University of Maryland BioPark to this week’s Money Moves.

Gliknik, a company developing treatments for people with cancer and autoimmune diseases, announced completion of its Series C round.

The company raised $11.5 million in a round led by First in Ventures (FIV). Also participating were SAISO Partners, and affiliates of RDA Ventures and Garden Street Holdings.

“We believe that Gliknik has created several potential best-in-class mid-stage assets,” said Scott Roth, managing partner of FIV, in a statement. “This capital will help unlock the potential of these compounds and uniquely positions Gliknik to make a difference for patients with cancer or autoimmune disorders.”

The funding will help the company progress on trial work for three of its treatments in development. They include:

  • biropepimut-S, which is in a clinical trial phase. This is designed for high-risk squamous cell cancer of the oral cavity.
  • GL-2045, which treats autoimmune diseases. It is under development by Pfizer, to which Gliknik licensed technology.
  • GL-0719, which is “designed to control diseases while leaving critical host systems intact,” the company said in a statement. It is slated for a clinical trial in 2021.

The company also has additional treatments in its pipeline that the funding will help develop.

In all, 14-year-old Gliknik has now raised $81 million in funding. The company is among a group of businesses developing new kinds of therapeutics and treatments for diseases that are clustered around the city’s health and research institutions.

Companies: Gliknik / University of Maryland BioPark

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

3 ways to support our work:
  • Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
  • Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
  • Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
The journalism fund Preferred partners Our services
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

Trump may kill the CHIPS and Science Act. Here’s what that means for your community.

Despite big raises and contracts, a tech training giant lays off staffers and loses its CEO

14 tech community events to be thankful for in November

How 4 orgs give back to their local tech community

Technically Media